Sugammadex + Succinylcholine + Rocuronium

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anesthesia, General

Conditions

Anesthesia, General

Trial Timeline

Feb 10, 2006 โ†’ Sep 9, 2006

About Sugammadex + Succinylcholine + Rocuronium

Sugammadex + Succinylcholine + Rocuronium is a phase 3 stage product being developed by Merck for Anesthesia, General. The current trial status is completed. This product is registered under clinical trial identifier NCT00474253. Target conditions include Anesthesia, General.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00474253Phase 3Completed

Competing Products

20 competing products in Anesthesia, General

See all competitors